Global Rapid Diagnostic Tests (RDT) Market - Industry Trends And Forecast To 2029
- Published Date: 2022-11-21
- Report ID: 144495
- Pages: 200
-
Format:
Short Description
Global Rapid Diagnostic Tests (RDT) Market, By Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic, Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, South Africa, Nigeria, Ethiopia and Rest of Africa) Industry Trends and Forecast to 2029
Market Definition:
The rapid diagnostic tests, also called rapid tests, are easy-to-use tests that offer quick results, usually in less than 20 minutes. Unlike other standard and conventional tests, where the diagnosis and sampling are sent to the laboratory, the results obtained from rapid diagnostic test kits are provided at the point of care. The point of care is a place where the patients get cured. The point of care can be a providers office, a clinic, or a patients own house.
The RDTs are applicable for diagnosing and testing infectious diseases such as COVID-19, cardiology diseases, oncology, pregnancy, fertility testing, toxicology testing, drugs-of-abuse testing, cardiometabolic testing, and glucose monitoring.
The currently available technological developments in rapid diagnostics testing are the reverse transcriptase-polymerase chain reaction (RT-PCR), RT-LAMP, enzyme-linked immunosorbent assay (ELISA), and Next Generation Sequencing (NGS). The developments in the testing kits provide an effective strategy to implement robust identification and diagnosis of the pathogen. The digital approach to rapid diagnostic tests allows the research team to understand and obtain, real time-results. The use of lateral flow testing is increasing, and it has to go digital for societies to get maximum benefits from it.
Market Segmentation:
The global rapid diagnostic tests (RDT) market is categorized into eleven notable segments based on product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel.
On the basis of product type, the global rapid diagnostic tests (RDT) market is segmented into consumables and kits, instruments, and others
On the basis of mode, the global rapid diagnostic tests (RDT) market is segmented into professional rapid diagnostic test product, and over-the-counter [OTC] rapid diagnostic test product
On the basis of technology, the global rapid diagnostic tests (RDT) market is segmented into PCR-based, flow-through assays, lateral flow immunochromatographic assays, agglutination assay, microfluidics, substrate technology, and others
On the basis of modality, the global rapid diagnostic tests (RDT) market is segmented into laboratory based test and non-laboratory based test
On the basis of age group, the global rapid diagnostic tests (RDT) market is segmented into adult and pediatric
On the basis of test type, the global rapid diagnostic tests (RDT) market is segmented into determining confirmation, serological testing, and viral sequencing
On the basis of approach, the global rapid diagnostic tests (RDT) market is segmented into in-vitro diagnostic and molecular diagnostic
On the basis of specimen, the global rapid diagnostic tests (RDT) market is segmented into swab, blood, urine, saliva, sputum, and others
On the basis of application, the global rapid diagnostic tests (RDT) market is segmented into infectious disease testing, glucose monitoring, cardiology testing, oncology testing, cardiometabolic testing, drugs-of-abuse testing, pregnancy & fertility testing, toxicology testing, and others
On the basis of end user, the global rapid diagnostic tests (RDT) market is segmented into hospital & clinic, diagnostic laboratory, home care setting, research and academic institutes, and others
On the basis of distribution channel, the global rapid diagnostic tests (RDT) market is segmented into direct tender, retail sales, and others
Market Players
Some of the key market players for the global rapid diagnostic tests (RDT) market are listed below:
Abbott
Danaher
Cellex
AdvaCare Pharma
Access Bio
Cardinal Health
Bio-Rad Laboratories, Inc.
BD
F. Hoffmann-La Roche Ltd
bioMrieux SA
InBios International, Inc.
Gnomegen LLC
QIAGEN
Quidel Corporation
Chembio Diagnostics Systems, Inc.
Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG)
PerkinElmer Inc.
Sekisui Diagnostics
Fujirebio (A Subsidiary of H.U. Group)
PTS Diagnostics
LamdaGen Corporation
Werfen
Nova Biomedical
Trinity Biotech
Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation)
Luminex Corporation. A DiaSorin Company
MEGAKOR DIAGNOSTK GMBH
TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE GLOBAL RAPID DIAGNOSTIC TESTS (RTD) MARKET 56
1.4 CURRENCY AND PRICING 58
1.5 LIMITATIONS 58
1.6 MARKETS COVERED 58
2 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET: SEGMENTATION 63
2.1 MARKETS COVERED 63
2.2 GEOGRAPHICAL SCOPE 64
2.3 YEARS CONSIDERED FOR THE STUDY 65
2.4 DBMR TRIPOD DATA VALIDATION MODEL 66
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 69
2.6 MULTIVARIATE MODELLING 70
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 70
2.8 DBMR MARKET POSITION GRID 71
2.9 VENDOR SHARE ANALYSIS 73
2.10 MARKET APPLICATION COVERAGE GRID 74
2.11 SECONDARY SOURCES 75
3 EXECUTIVE SUMMARY 76
4 PREMIUM INSIGHTS 79
5 MARKET OVERVIEW 81
5.1 DRIVERS 83
5.1.1 INCREASE IN INCIDENCE OF CHRONIC DISEASES 83
5.1.2 RISE IN GERIATRIC POPULATION 84
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN THE RAPID DIAGNOSTIC TESTING 85
5.1.4 GOVERNMENT INITIATIVES FOR DIAGNOSIS OF INFECTIOUS DISEASES 85
5.1.5 RISE IN PRODUCT LAUNCHES 85
5.2 RESTRAINTS 86
5.2.1 HIGH COST ASSOCIATED WITH THE RAPID DIAGNOSTIC KITS 86
5.2.2 OPERATIONAL BARRIERS FACED WHILE CONDUCTING RAPID DIAGNOSTIC TESTS 86
5.2.3 PRODUCT RECALLS IN RAPID DIAGNOSTIC TESTS 87
5.2.4 LACK OF AWARENESS ABOUT RAPID DIAGNOSTIC TESTING 87
5.3 OPPORTUNITIES 87
5.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 87
5.3.2 RISING GOVERNMENT FUNDING 88
5.3.3 INCREASING HEALTHCARE EXPENDITURE 88
5.4 CHALLENGES 89
5.4.1 STRINGENT REGULATORY FOR MARKET APPROVAL 89
5.4.2 LACK OF TRAINING 89
6 IMPACT OF COVID-19 ON GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET 91
6.1 IMPACT ON PRICE 91
6.2 IMPACT ON SUPPLY CHAIN 91
6.3 IMPACT ON DEMAND 92
6.4 STRATEGIC INITIATIVES BY MANUFACTURERS 92
6.5 CONCLUSION 92
7 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY PRODUCT TYPE 94
7.1 OVERVIEW 95
7.2 CONSUMABLES AND KITS 98
7.2.1 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 99
7.2.2 IMMUNOCHROMATOGRAPHIC ASSAY 99
7.2.2.1 ANTIBODY TESTS 99
7.2.2.1.1 TOTAL ANTIBODY ELISA KIT 100
7.2.2.1.2 IGM/IGG RAPID DIAGNOSTIC TEST 100
7.2.2.1.3 IGG ELISA KIT 100
7.2.2.1.4 IGM ELISA KIT 100
7.2.2.1.5 NEUTRALIZING ANTIBODY ELISA KIT 100
7.2.2.2 ANTIGEN ELISA KITS 100
7.2.2.3 SPECIMEN COLLECTION KIT 101
7.2.3 RT-PCR ASSAY KITS 101
7.2.3.1 REVERSE TRANSCRIPTION PCR (RT-PCR) 101
7.2.3.2 QUANTITATIVE REVERSE TRANSCRIPTION PCR (RT-QPCR) 101
7.2.4 OTHERS 101
7.3 INSTRUMENTS 101
7.3.1 PORTABLE 102
7.3.2 BENCHTOP 102
7.3.3 FIXED 102
7.4 OTHERS 102
8 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODE 104
8.1 OVERVIEW 105
8.2 PROFESSIONAL 108
8.3 OVER-THE-COUNTER [OTC] 109
9 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TECHNOLOGY 110
9.1 OVERVIEW 111
9.2 PCR-BASED 114
9.3 FLOW-THROUGH ASSAYS 114
9.4 LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAYS 115
9.5 AGGLUTINATION ASSAY 115
9.6 MICROFLUIDICS 116
9.6.1 PAPER-BASED MICROFLUDICS 117
9.6.2 LUCIFERASE IMMUNOPRECIPITATION SYSTEMS (LIPS) 117
9.6.3 OTHERS 117
9.7 SUBSTRATE TECHNOLOGY 117
9.8 OTHERS 118
10 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY MODALITY 119
10.1 OVERVIEW 120
10.2 LABORATORY BASED TEST 123
10.3 NON-LABORATORY BASED TEST 123
11 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY AGE GROUP 125
11.1 OVERVIEW 126
11.2 ADULT 129
11.3 PEDIATRIC 129
12 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY TEST TYPE 130
12.1 OVERVIEW 131
12.2 DETERMINING CONFIRMATION 134
12.2.1 RT-PCR ASSAY KITS 134
12.2.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 134
12.2.3 IMMUNOCHROMATOGRAPHIC ASSAY 135
12.2.4 OTHERS 135
12.3 SEROLOGICAL TESTING 135
12.3.1 RT-PCR ASSAY KITS 136
12.3.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 136
12.3.3 IMMUNOCHROMATOGRAPHIC ASSAY 136
12.3.4 OTHERS 136
12.4 VIRAL SEQUENCING 136
12.4.1 RT-PCR ASSAY KITS 137
12.4.2 RAPID IMMUNOASSAY TEST STRIPS/CASSETTES 137
12.4.3 IMMUNOCHROMATOGRAPHIC ASSAY 137
12.4.4 OTHERS 137
13 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPROACH 138
13.1 OVERVIEW 139
13.2 IN-VITRO DIAGNOSTIC 142
13.3 MOLECULAR DIAGNOSTIC 142
14 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY SPECIMEN 143
14.1 OVERVIEW 144
14.2 SWAB 147
14.3 BLOOD 147
14.4 URINE 148
14.5 SALIVA 148
14.6 SPUTUM 149
14.7 OTHERS 149
15 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY APPLICATION 151
15.1 OVERVIEW 152
15.2 INFECTIOUS DISEASE TESTING 155
15.2.1 VIRUS 156
15.2.2 BACTERIA 156
15.2.3 OTHERS 156
15.3 GLUCOSE MONITORING 156
15.4 CARDIOLOGY TESTING 157
15.5 ONCOLOGY TESTING 157
15.5.1 LUNG CANCER 158
15.5.2 BREAST CANCER 158
15.5.3 BLOOD CANCER 158
15.5.4 OTHERS 158
15.6 CARDIOMETABOLIC TESTING 158
15.7 DRUGS-OF-ABUSE TESTING 159
15.8 PREGNANCY & FERTILITY TESTING 159
15.9 TOXICOLOGY TESTING 160
15.10 OTHERS 160
16 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY END USER 162
16.1 OVERVIEW 163
16.2 HOSPITAL & CLINIC 165
16.3 DIAGNOSTIC LABORATORY 166
16.4 HOME CARE SETTING 167
16.5 RESEARCH AND ACADEMIC INSTITUTES 167
16.6 OTHERS 168
17 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY DISTRIBUTION CHANNEL 169
17.1 OVERVIEW 170
17.2 DIRECT TENDER 173
17.3 RETAIL SALES 173
18 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET, BY REGION 175
18.1 GLOBAL 176
18.2 NORTH AMERICA 182
18.2.1 U.S. 193
18.2.2 CANADA 199
18.2.3 MEXICO 205
18.3 EUROPE 211
18.3.1 GERMANY 223
18.3.2 FRANCE 230
18.3.3 U.K. 236
18.3.4 ITALY 242
18.3.5 SPAIN 248
18.3.6 RUSSIA 254
18.3.7 TURKEY 260
18.3.8 BELGIUM 266
18.3.9 NETHERLANDS 272
18.3.10 SWITZERLAND 279
18.3.11 REST OF EUROPE 285
18.4 ASIA-PACIFIC 286
18.4.1 CHINA 298
18.4.2 JAPAN 304
18.4.3 SOUTH KOREA 310
18.4.4 INDIA 317
18.4.5 AUSTRALIA 323
18.4.6 SINGAPORE 330
18.4.7 THAILAND 336
18.4.8 MALAYSIA 342
18.4.9 INDONESIA 348
18.4.10 PHILIPPINES 354
18.4.11 REST OF ASIA-PACIFIC 360
18.5 SOUTH AMERICA 361
18.5.1 BRAZIL 372
18.5.2 ARGENTINA 378
18.5.3 REST OF SOUTH AMERICA 384
18.6 AFRICA 385
18.6.1 SOUTH AFRICA 396
18.6.2 NIGERIA 403
18.6.3 ETHIOPIA 409
18.6.4 REST OF AFRICA 415
19 GLOBAL RAPID DIAGNOSTIC TESTS (RDT) MARKET: COMPANY LANDSCAPE 416
19.1 COMPANY SHARE ANALYSIS: GLOBAL 416
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 417
19.3 COMPANY SHARE ANALYSIS: EUROPE 418
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 419
20 SWOT ANALYSIS 420
21 COMPANY SHARE ANALYSIS 421
21.1 ABBOTT 421
21.1.1 COMPANY SNAPSHOT 421
21.1.2 REVENUE ANALYSIS 421
21.1.3 COMPANY SHARE ANALYSIS 422
21.1.4 PRODUCT PORTFOLIO 423
21.1.5 RECENT DEVELOPMENTS 423
21.2 F. HOFFMANN-LA ROCHE LTD 424
21.2.1 COMPANY SNAPSHOT 424
21.2.2 REVENUE ANALYSIS 424
21.2.3 COMPANY SHARE ANALYSIS 425
21.2.4 PRODUCT PORTFOLIO 426
21.2.5 RECENT DEVELOPMENTS 426
21.3 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG) 427
21.3.1 COMPANY SNAPSHOT 427
21.3.2 REVENUE ANALYSIS 427
21.3.3 COMPANY SHARE ANALYSIS 428
21.3.4 PRODUCT PORTFOLIO 429
21.3.5 RECENT DEVELOPMENTS 430
21.4 CARDINAL HEALTH 431
21.4.1 COMPANY SNAPSHOT 431
21.4.2 REVENUE ANALYSIS 431
21.4.3 COMPANY SHARE ANALYSIS 432
21.4.4 PRODUCT PORTFOLIO 433
21.4.5 RECENT DEVELOPMENT 433
21.5 QUIDEL CORPORATION 434
21.5.1 COMPANY SNAPSHOT 434
21.5.2 REVENUE ANALYSIS 434
21.5.3 COMPANY SHARE ANALYSIS 435
21.5.4 PRODUCT PORTFOLIO 436
21.5.5 RECENT DEVELOPMENTS 437
21.6 ADVACARE PHARMA 438
21.6.1 COMPANY SNAPSHOT 438
21.6.2 PRODUCT PORTFOLIO 438
21.6.3 RECENT DEVELOPMENT 438
21.7 ACCESS BIO 439
21.7.1 COMPANY SNAPSHOT 439
21.7.2 PRODUCT PORTFOLIO 439
21.7.3 RECENT DEVELOPMENTS 440
21.8 BD 441
21.8.1 COMPANY SNAPSHOT 441
21.8.2 REVENUE ANALYSIS 441
21.8.3 PRODUCT PORTFOLIO 442
21.8.4 RECENT DEVELOPMENTS 442
21.9 BIOMRIEUX SA 443
21.9.1 COMPANY SNAPSHOT 443
21.9.2 REVENUE ANALYSIS 443
21.9.3 PRODUCT PORTFOLIO 444
21.9.4 RECENT DEVELOPMENT 444
21.10 BIO-RAD LABORATORIES, INC. 445
21.10.1 COMPANY SNAPSHOT 445
21.10.2 REVENUE ANALYSIS 445
21.10.3 PRODUCT PORTFOLIO 446
21.10.4 RECENT DEVELOPMENTS 446
21.11 CELLEX 447
21.11.1 COMPANY SNAPSHOT 447
21.11.2 PRODUCT PORTFOLIO 447
21.11.3 RECENT DEVELOPMENTS 447
21.12 CHEMBIO DIAGNOSTICS SYSTEMS, INC. 448
21.12.1 COMPANY SNAPSHOT 448
21.12.2 REVENUE ANALYSIS 448
21.12.3 PRODUCT PORTFOLIO 449
21.12.4 RECENT DEVELOPMENTS 449
21.13 DANAHER 450
21.13.1 COMPANY SNAPSHOT 450
21.13.2 REVENUE ANALYSIS 450
21.13.3 PRODUCT PORTFOLIO 451
21.13.4 RECENT DEVELOPMENTS 451
21.14 FUJIREBIO (A SUBSIDIARY OF H.U. GROUP) 452
21.14.1 COMPANY SNAPSHOT 452
21.14.2 REVENUE ANALYSIS 452
21.14.3 PRODUCT PORTFOLIO 453
21.14.4 RECENT DEVELOPMENTS 453
21.15 GNOMEGAN LLC 454
21.15.1 COMPANY SNAPSHOT 454
21.15.2 PRODUCT PORTFOLIO 454
21.15.3 RECENT DEVELOPMENT 454
21.16 INBIOS INTERNATIONAL, INC 455
21.16.1 COMPANY SNAPSHOT 455
21.16.2 PRODUCT PORTFOLIO 455
21.16.3 RECENT DEVELOPMENTS 456
21.17 LAMDAGEN CORPORATION. 457
21.17.1 COMPANY SNAPSHOT 457
21.17.2 PRODUCT PORTFOLIO 457
21.17.3 RECENT DEVELOPMENTS 457
21.18 LUMINEX CORPORATION, A DIASORIN COMPANY 459
21.18.1 COMPANY SNAPSHOT 459
21.18.2 REVENUE ANALYSIS 459
21.18.3 PRODUCT PORTFOLIO 460
21.18.4 RECENT DEVELOPMENT 460
21.19 MEGAKOR DIAGNOSTIK GMBH 461
21.19.1 COMPANY SNAPSHOT 461
21.19.2 PRODUCT PORTFOLIO 461
21.19.3 RECENT DEVELOPMENT 461
21.20 NOVA BIOMEDICAL 462
21.20.1 COMPANY SNAPSHOT 462
21.20.2 PRODUCT PORTFOLIO 462
21.20.3 RECENT DEVELOPMENTS 463
21.21 PERKIN ELMER INC. 464
21.21.1 COMPANY SNAPSHOT 464
21.21.2 REVENUE ANALYSIS 464
21.21.3 PRODUCT PORTFOLIO 465
21.21.4 RECENT DEVELOPMENTS 466
21.22 PTS DIAGNOSTICS 467
21.22.1 COMPANY SNAPSHOT 467
21.22.2 PRODUCT PORTFOLIO 467
21.22.3 RECENT DEVELOPMENTS 468
21.23 QIAGEN 469
21.23.1 COMPANY SNAPSHOT 469
21.23.2 REVENUE ANALYSIS 469
21.23.3 PRODUCT PORTFOLIO 470
21.23.4 RECENT DEVELOPMENT 470
21.24 SEKISUI DIAGNOSTICS 471
21.24.1 COMPANY SNAPSHOT 471
21.24.2 PRODUCT PORTFOLIO 471
21.24.3 RECENT DEVELOPMENTS 472
21.25 SYSMEX EUROPE GMBH (A SUBSIDIARY OF SYSMEX CORPORATION) 473
21.25.1 COMPANY SNAPSHOT 473
21.25.2 REVENUE ANALYSIS 473
21.25.3 PRODUCT PORTFOLIO 474
21.25.4 RECENT DEVELOPMENTS 474
21.26 TRINITY BIOTECH 475
21.26.1 COMPANY SNAPSHOT 475
21.26.2 REVENUE ANALYSIS 475
21.26.3 PRODUCT PORTFOLIO 476
21.26.4 RECENT DEVELOPMENT 476
21.27 WERFEN 477
21.27.1 COMPANY SNAPSHOT 477
21.27.2 PRODUCT PORTFOLIO 477
21.27.3 RECENT DEVELOPMENT 477
22 QUESTIONNAIRE 478
23 RELATED REPORTS 483
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
